A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

NCT02025907 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

218

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Canagliflozin, 100 mg
DRUG: Canagliflozin, 300 mg
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC